BrainStorm Cell Therapeutics Inc. announced it has received Good Manufacturing Practice (GMP) approval from the Israel Ministry of Health (MoH) for its Israeli contract manufacturing facility. The GMP certificate confirms the company's manufacturing site compliance with Israeli GMPs which are recognized as equivalent with EU GMP. This approval paves the way for the company's application to the Israel MoH for the treatment of ALS patients in Israel for a fee, under the newly introduced Hospital Exemption regulation. The GMP certificate was granted after an inspection of BrainStorm's contract manufacturing facilities.